Related Experiment Video

Updated: May 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

A new generation of oral direct anticoagulants

Gerald A Soff1

  • 1Hematology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-802, New York, NY 10065, USA. soffg@mskcc.org

Arteriosclerosis, Thrombosis, and Vascular Biology
|February 21, 2012
PubMed

Insights

New direct oral anticoagulants offer alternatives to traditional blood thinners like heparin. Recent trials evaluated these novel anticoagulants for conditions including atrial fibrillation and venous thromboembolic events.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Hematology

Background:

  • Heparin and vitamin K antagonists have long been mainstays for thrombosis treatment and prophylaxis.
  • A new generation of oral, direct anticoagulants has emerged, representing a significant shift in anticoagulant therapy.

Purpose of the Study:

  • To review the latest clinical trial data on new oral anticoagulants.
  • To focus on dabigatran, rivaroxaban, and apixaban for thrombosis treatment and prophylaxis.

Main Methods:

  • Review of recent clinical trials evaluating new oral anticoagulants.
  • Focus on studies in nonvalvular atrial fibrillation, thrombosis prophylaxis post-joint replacement, venous thromboembolic events, and acute coronary syndrome.
  • Analysis of trials for dabigatran, rivaroxaban, and apixaban.

Main Results:

  • A large number of trials have evaluated new oral anticoagulants in diverse clinical settings over the past 5 years.
  • Studies for specific indications show notable similarities in design across different drugs.
  • Dabigatran and rivaroxaban are FDA-approved; apixaban has mature phase III data.

Conclusions:

  • New oral anticoagulants represent a significant advancement in anticoagulation therapy.
  • These agents are increasingly utilized across various thrombotic and cardiovascular conditions.
  • Further research and clinical experience will continue to define their role in patient care.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...